Illumina Inc
Find Ratings Reports
-1.14 |
-0.59%
ILLUMINA INC's gross profit margin for the second quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. ILLUMINA INC is extremely liquid. Currently, the Quick Ratio is 3.32 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 32.06% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Net Sales ($mil) | 663.0 | 600.12 |
| EBITDA ($mil) | 173.0 | 185.73 |
| EBIT ($mil) | 135.0 | 151.38 |
| Net Income ($mil) | 128.0 | 120.41 |
| Balance Sheet | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Cash & Equiv. ($mil) | 1893.0 | 1425.26 |
| Total Assets ($mil) | 4858.0 | 3985.09 |
| Total Debt ($mil) | 1174.0 | 1031.88 |
| Equity ($mil) | 2715.0 | 2055.77 |
| Profitability | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Gross Profit Margin | 71.19 | 76.34 |
| EBITDA Margin | 26.09 | 30.94 |
| Operating Margin | 20.36 | 25.22 |
| Sales Turnover | 0.51 | 0.58 |
| Return on Assets | 15.39 | 10.85 |
| Return on Equity | 27.53 | 21.04 |
| Debt | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Current Ratio | 3.88 | 3.69 |
| Debt/Capital | 0.3 | 0.33 |
| Interest Expense | 8.0 | 8.15 |
| Interest Coverage | 16.88 | 18.58 |
| Share Data | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Shares outstanding (mil) | 146.0 | 146.6 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.87 | 0.82 |
| Book value / share | 18.6 | 14.02 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 996268.0 | 993182.0 |
BUY. The current P/E ratio indicates a significant discount compared to an average of 64.41 for the Life Sciences Tools & Services industry and a significant premium compared to the S&P 500 average of 24.23. For additional comparison, its price-to-book ratio of 10.28 indicates a significant premium versus the S&P 500 average of 3.02 and a significant premium versus the industry average of 6.29. The current price-to-sales ratio is well above the S&P 500 average and above the industry average, indicating a premium.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN 37.79 | Peers 64.41 | ILMN 35.95 | Peers 30.27 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. ILMN is trading at a significant discount to its peers. |
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. ILMN is trading at a premium to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| ILMN 43.85 | Peers 29.05 | ILMN 2.00 | Peers 0.95 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. ILMN is trading at a significant premium to its peers. |
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. ILMN trades at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| ILMN 10.28 | Peers 6.29 | ILMN 73.88 | Peers 13.54 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. ILMN is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. ILMN is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| ILMN 11.22 | Peers 10.96 | ILMN 7.51 | Peers 12.27 | |||||||||||||||||||||
|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. ILMN is trading at a valuation on par with its industry on this measurement. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. ILMN significantly trails its peers on the basis of sales growth |
|||||||||||||||||||||||
